Recessive multiple epiphyseal dysplasia Clinical Trials

• UAB Recessive PKD Research and Translational Core Center
  ClinicalTrials.gov Identifier: NCT00575705 - Recruiting
  Autosomal Recessive Polycystic Kidney Disease
  
• Evaluation of Autosomal Recessive Polycystic Kidney Disease and Congenital Hepatic Fibrosis
  ClinicalTrials.gov Identifier: NCT00068224 - Recruiting
  Polycystic Kidney, Autosomal Recessive
  
• Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
  ClinicalTrials.gov Identifier: NCT00001728 - Active, not recruiting
  Polyostotic Fibrous Dysplasia
  
• Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia
  ClinicalTrials.gov Identifier: NCT00067613 - Active, not recruiting
  Bronchopulmonary Dysplasia
  
• Screening and Natural History of Patients with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
  ClinicalTrials.gov Identifier: NCT00001727 - Recruiting
  Polyostotic Fibrous Dysplasia
  
• Studies on Abnormal Bone from Patients with Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
  ClinicalTrials.gov Identifier: NCT00001973 - Recruiting
  Polyostotic Fibrous Dysplasia
  
• Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer
  ClinicalTrials.gov Identifier: NCT00533572 - Recruiting
  Recessive Dystrophic Epidermolysis Bullosa
  
• Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
  ClinicalTrials.gov Identifier: NCT00001851 - Recruiting
  Polyostotic Fibrous Dysplasia
  
• Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project)
  ClinicalTrials.gov Identifier: NCT00005289 - Active, not recruiting
  Bronchopulmonary Dysplasia; Lung Diseases; Respiratory Distress Syndrome
  
• A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia
  ClinicalTrials.gov Identifier: NCT00374114 - Recruiting
  Cervical Dysplasia
  
• Inhaled NO for the Prevention of Chronic Lung Disease
  ClinicalTrials.gov Identifier: NCT00006401 - Active, not recruiting
  Lung Diseases; Bronchopulmonary Dysplasia
  
• Inhaled NO in Prevention of Chronic Lung Disease
  ClinicalTrials.gov Identifier: NCT00000548 - Active, not recruiting
  Bronchopulmonary Dysplasia; Lung Diseases
  
• Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia
  ClinicalTrials.gov Identifier: NCT00212381 - Recruiting
  Cervical Dysplasia
  
• Digital Imaging Aid for Assessment of Cervical Dysplasia
  ClinicalTrials.gov Identifier: NCT00511758 - Recruiting
  Cervical Dysplasia
  
• Wild Type p53 Adenovirus for Oral Premalignancies
  ClinicalTrials.gov Identifier: NCT00410865 - Active, not recruiting
  Mouth Cancer; Dysplasia/Carcinoma in Situ (CIS) of the Oral Cavity; Dysplasia/Carcinoma in Situ (CIS) of the Oral Pharynx
  
• Vaccine Therapy Plus GM-CSF in Treating Patients With Multiple Myeloma Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00002787 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• A Study to Evaluate Rituximab in Adults with Relapsing Remitting Multiple Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00097188 - Active, not recruiting
  Multiple Sclerosis
  
• Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00088855 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy and Interferon alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
  ClinicalTrials.gov Identifier: NCT00002599 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004903 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Bortezomib in Combination with CC-5013 in Patients with Relapsed/Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00153933 - Active, not recruiting
  Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple Myeloma
  
• Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002556 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003490 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Multidisciplinary Study of Right Ventricular Dysplasia
  ClinicalTrials.gov Identifier: NCT00024505 - Recruiting
  Heart Diseases; Ventricular Arrhythmia; Arrhythmogenic Right Ventricular Dysplasia
  
• Combination Chemotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002678 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00098475 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Dexamethasone With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00064038 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants
  ClinicalTrials.gov Identifier: NCT00167544 - Recruiting
  Bronchopulmonary Dysplasia; Encephalomalacia; Premature Birth
  
• BEYOND Study - Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
  ClinicalTrials.gov Identifier: NCT00099502 - Active, not recruiting
  Multiple Sclerosis
  
• Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
  ClinicalTrials.gov Identifier: NCT00445575 - Recruiting
  Fibrous Dysplasia of Bone
  
• Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003954 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Safety of RG2077 in Patients With Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00076934 - Active, not recruiting
  Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
  
• Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Phase III Randomized Study of Melphalan With or Without Holmium Ho 166 DOTMP Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00008229 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Rebif® New Formulation in Relapsing Forms of Multiple Sclerosis (RMS)
  ClinicalTrials.gov Identifier: NCT00110396 - Active, not recruiting
  Multiple Sclerosis
  
• Combination Therapy with Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00037102 - Active, not recruiting
  Multiple Sclerosis
  
• T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
  ClinicalTrials.gov Identifier: NCT00048464 - Active, not recruiting
  Multiple Myeloma
  
• Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00017602 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003603 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Ablation of Intestinal Metaplasia Containing Dysplasia
  ClinicalTrials.gov Identifier: NCT00282672 - Active, not recruiting
  Barrett's Esophagus
  
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00005792 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00080405 - Active, not recruiting
  Multiple Myeloma
  
• Evaluating Materials to Educate Patients
  ClinicalTrials.gov Identifier: NCT00454766 - Active, not recruiting
  Education; Cervical Dysplasia
  
• Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00040937 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006219 - Active, not recruiting
  Multiple Myeloma
  
• Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00014508 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00095680 - Active, not recruiting
  Multiple Myeloma
  
• A Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00087529 - Active, not recruiting
  Multiple Sclerosis
  
• High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
  ClinicalTrials.gov Identifier: NCT00002630 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma
  ClinicalTrials.gov Identifier: NCT00065351 - Active, not recruiting
  Multiple Myeloma
  
• Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
  ClinicalTrials.gov Identifier: NCT00002850 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection
  
• VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients with Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00111319 - Active, not recruiting
  Multiple Myeloma
  
• Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00024466 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Auditory Function in Patients With and Without Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00037947 - Recruiting
  Multiple Sclerosis
  
• Immunotherapy with BHT-3009 Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00103974 - Active, not recruiting
  Multiple Sclerosis
  
• Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00087867 - Active, not recruiting
  Multiple Myeloma
  
• Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004158 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
  
• Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia
  ClinicalTrials.gov Identifier: NCT00303368 - Recruiting
  Neurofibromatosis Type 1; Tibial Dysplasia
  
• Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00021359 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002653 - Active, not recruiting
  Multiple Myeloma
  
• Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004165 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
  
• Pilot Study of Familial Nonsyndromal Mondini Dysplasia
  ClinicalTrials.gov Identifier: NCT00004336 - Completed
  Mondini dysplasia
  
• Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00049673 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00002548 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00113919 - Active, not recruiting
  Multiple Myeloma
  
• Thal/Dex (Thalidomide and Dexamethasone) vs. Dd-T (Doxil, Dexamethasone and Thalidomide) in Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00097981 - Active, not recruiting
  Multiple Myeloma
  
• A Randomized Trial of Surgical Treatments for Vulvar and Vaginal Dysplasia
  ClinicalTrials.gov Identifier: NCT00394758 - Completed
  Vulvar Dysplasia; Vaginal Dysplasia
  
• Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004088 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00021203 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Melphalan and Prednisone With or Without Bortezomib in Treating Older Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00109902 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006244 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00057564 - Active, not recruiting
  Multiple Myeloma
  
• Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00045136 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00075881 - Active, not recruiting
  stage III multiple myeloma
  
• Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00411723 - Recruiting
  Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting
  
• CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00056160 - Active, not recruiting
  Multiple Myeloma
  
• Study of DOXIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00103506 - Active, not recruiting
  Multiple Myeloma
  
• Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00151203 - Active, not recruiting
  Multiple Myeloma
  
• EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00137176 - Recruiting
  Multiple Sclerosis
  
• EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00146068 - Recruiting
  Multiple Sclerosis
  
• Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia
  ClinicalTrials.gov Identifier: NCT00004669 - Completed
  Bronchopulmonary Dysplasia
  
• Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
  ClinicalTrials.gov Identifier: NCT00220493 - Recruiting
  Relapsing Remitting Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
  
• Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis With Optional Extension Phase
  ClinicalTrials.gov Identifier: NCT00340834 - Active, not recruiting
  Multiple Sclerosis
  
• Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00316940 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00186238 - Active, not recruiting
  Multiple Myeloma
  
• Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
  ClinicalTrials.gov Identifier: NCT00186316 - Active, not recruiting
  Multiple Myeloma
  
• Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00246324 - Active, not recruiting
  Multiple Sclerosis
  
• GER-009-06-AVX Early Therapy in Multiple Sclerosis
  ClinicalTrials.gov Identifier: NCT00492570 - Active, not recruiting
  Relapsing-Remitting Multiple Sclerosis
  
• Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00317811 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Extension Study to Evaluate Safety, Tolerability and Effects on Efficacy Parameters of FTY720 in Patients With Relapsing Multiple Sclerosis.
  ClinicalTrials.gov Identifier: NCT00235430 - Active, not recruiting
  Multiple Sclerosis
  
• Prospective, Open-Label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
  ClinicalTrials.gov Identifier: NCT00262314 - Active, not recruiting
  Multiple Sclerosis
  
• Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00046852 - Active, not recruiting
  Infection; refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
  ClinicalTrials.gov Identifier: NCT00257114 - Active, not recruiting
  Multiple Myeloma
  
• Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00028886 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib (Velcade) in Patients with Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00153920 - Active, not recruiting
  Multiple Myeloma
  
• The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00207805 - Active, not recruiting
  Multiple Myeloma
  
• A Multicentre, Single-Arm, Open-Label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00420849 - Active, not recruiting
  Multiple Myeloma
  
• Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00114101 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma